NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEGLUJAN is a fixed-dose oral tablet combining ertugliflozin (an SGLT2 inhibitor) and sitagliptin (a DPP-4 inhibitor) approved by the FDA in December 2017. It is indicated for type 2 diabetes mellitus in adults as an adjunctive treatment to diet and exercise. The dual mechanism addresses hyperglycemia through distinct pathways: SGLT2 inhibition promotes urinary glucose excretion while DPP-4 inhibition enhances incretin-mediated insulin secretion.
$0.001BPart D
Peak5.4 years to LOEThe product is at peak lifecycle stage with modest Part D claims (~1,478 in 2023), suggesting stable but limited market penetration; brand teams are likely focused on lifecycle management and retention rather than aggressive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Started Apr 2014
1,233 enrolled
Type 2 Diabetes Mellitus
Career Relevance
Working on STEGLUJAN offers experience in a mature specialty diabetes franchise with established commercial infrastructure, but limited growth upside; career development is best suited for professionals seeking deep expertise in combination therapy marketing, payer negotiations, and lifecycle extension strategies ahead of generic competition. The transition to LOE phase (beginning 2026) will shift priorities toward defensive positioning and cost optimization.
Brand Manager
Worked on STEGLUJAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.